User notice: We are aware of the issues affecting the Portfolio page. Our developers are working to resolve the problem as soon as possible. We apologise for the inconvenience.

Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Shares Traded Last Trade
  -19.00 -1.91% 975.00 137,974 16:35:00
Bid Price Offer Price High Price Low Price Open Price
982.00 985.00 1,006.00 964.00 1,006.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 87.73 -6.57 839
Last Trade Time Trade Type Trade Size Trade Price Currency
17:06:42 O 9 985.099 GBX

Oxford Biomedica (OXB) Latest News

More Oxford Biomedica News
Oxford Biomedica Investors    Oxford Biomedica Takeover Rumours

Oxford Biomedica (OXB) Discussions and Chat

Oxford Biomedica Forums and Chat

Date Time Title Posts
18/1/202221:29Feck off the_doctor14,507
18/1/202220:52OXB. One owner, FSH Excellent conditionwith ejector seat2,123
18/1/202220:35Open-minded posters thread92
08/1/202222:22Truth Vs. Deception77
07/1/202217:13Oxford Biomedica2,075

Add a New Thread

Oxford Biomedica (OXB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-01-18 17:06:43985.10988.66O
2022-01-18 17:03:09979.631521,489.03O
2022-01-18 17:00:13980.546446,314.70O
2022-01-18 16:58:28986.486516,421.98O
2022-01-18 16:56:25974.942582,515.33O
View all Oxford Biomedica trades in real-time

Oxford Biomedica (OXB) Top Chat Posts

Oxford Biomedica Daily Update: Oxford Biomedica Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 994p.
Oxford Biomedica Plc has a 4 week average price of 967p and a 12 week average price of 967p.
The 1 year high share price is 1,678p while the 1 year low share price is currently 914p.
There are currently 86,075,856 shares in issue and the average daily traded volume is 133,289 shares. The market capitalisation of Oxford Biomedica Plc is £839,239,596.
stocktastic: All simple imo - OXB share price was hyped up excessively on COVID Now that hype is subsiding, the share price is dropping back Rampers shout about Edison/Hardman type reports when they suggest Buy The last one published had a price target of around £10.50 ish Yet rampers will go on about how oversold this is
gigabit: Gareth - You are quite right about the reputation and exposure gained by the various partnerships you list. But apart from the Serum Institute investment, which strengthens the balance sheet but has no immediate impact on revenue, the others are very unlikely to bring business into the company other than in the medium to long term. Those are not factors that will affect the share price now - they might do in due course as and when their impact is measurable. I will certainly dip back in to OXB but have made no decision as to timing or at what level of share price they become a bargain. That is what makes investing so interesting.
stocktastic: "Harold is off on a bender again without knowing what he's talking about" Standard. And filters/bans/attacks anyone who has a different take Gigabit I am inclined to agree The ramper thread seems oblivious to the idea that the largest income line may have come and gone! The share price drop all gets blamed on an ambiguous and secretlu positive negative RNS and it is blindly assumed that this share price dip will be temporary, because profits can only go one way. Re takeover - I am more positive about that than you,but note how the largest shareholder dropped by last year to stir up takeover hopes and a £25 target....just as Serum was taking a stake. Coincidence or pushing rumours to help get that placing at a healthy price? The share price then slumped to £10 levels. I expect a drop below £8 when holders cotton on, IF 2022-23 income is going to be much lower
gigabit: As one who has dipped in and out of OXB several times over the past 10 years I am not surprised by the behaviour of the share price The vaccine bounce is now over and we are back to the pre-Covid price based on fundamentals. The prospect of a takeover bid is very low as the business model, predicated on a very long-term organic growth strategy, is unattractive to an acquirer. Any acquirer would also face getting into bed with multiple partners many of which may be actual or potential competitors. So any serious and sustained increase in share price will depend on one or more of the partnerships coming good which may well happen but not in the time-scale that most investors are interested in.
steeplejack: The algorithmic trades are executed in nanoseconds.In 2019,92% of trades in the FX market were made by algorithms.So,while i understand that humans might of programmed algorithms in the first instance,do they subsequently develop a life of their own,given free rein like some virus escaping from a Wuhan lab.I have next to no clue as to how a share price will react nowadays on results day.On occasions,apparent good figures trigger a sharp fall in the shares and visa-versa.Humans then spend time trying to rationalise the incomprehensible like trying to fathom the behaviour of ones dog when its let off its lead.Active fund managers have unenviable task.You can take solace in being a long term advisor but that doesn't make it that more palatable when say a solid company's share price plummets a quarter in 3 months for no obvious reason and they do!All those security industry qualifications acquired are worth not a jot in such a feral environment.Just toss a coin!
stocktastic: LoL. Still in denial! If the share price goes dowm on a negative RNS and questions around 2022 revenues.... it cannot be a negative. It must be spun and pushed as a positive. A positive with a magic curse that makes the share price go down "Harry S Truman6 Jan '22 - 09:12 - 2009 of 2012 0 2 0 It could be many things Jasie, not least OXB and their curse of positive news."
stocktastic: I dont personally have any issue with the bod and dont see much reason for things differing with or without Diggle. The Diggles' loan imo helped OXB at a time when I thought the company was seriously at risk of going bust. Whether their investment was supported by knowledge of the coming Novartis deal or not, I dont know, but they are one of few funds putting money into UK biotech and that is to be commended. OXB holders got lucky in the end - gene therapy finally went mainstream - something I always believed in. - CART had trial success and without anyone aware, OXB was set to provide the vector - the surprise of COVID I think this is relevant context behind what OXB does. The past failures/ struggles with internal projects have shown the big risk. Along history of money spent on candidates that got nowhere sadly - names long forgotten by most bulls. Allowed to by opportunities, the company has focused more on being a vector licensor/ manufacturer. This will give growth, but never the sorts of market cap that well funded US co.s with internal pipelines of late stage candidates command. They could move that way in time and I'd see that as the plan once finances allow "Also, during the COVID era, the lack of marketing of OXB's brilliant work on vaccine manufacture was alarming" I'm less convinced. While that could have generated a bigger short term bump, would it change 2022 on performance? I guess if it helped brimg in £200M that they could use to build the pipeline? Imo they tried a US listing twice. I forget now, but a series of events including the share consolidation, fit. Notable, there was a ramp in the share price for no reason. You'll note that Q3 this year, Tuco turned up to generate hope of a £25 per share takeover. I have seen this trick many times before and asked - what is he trying to achieve? As speculated, there was a placing not long sfter, to Serum.
stocktastic: "My tuppence worth on this share price fall , FWIW, is that, if this were a private company, we could not have ever been happier with how OXB is faring. It has never been in a stronger position and never better positioned for the future ." Generally a fair comment I'd say it was faring better a month ago though, surely? One way or another, the share price always finds its true path. Maybe it was overbought before? Or oversold now? We will have to wait and see how OXB's business performs over the coming years and THAT will determine the share price If more pipeline internal or partnered products are dropped, then OXB will not have new growth drivers. Conversely, if the existing and new pipeline agents do well,it is on upwards. My critique of OXB is actually not to be negative, but because I want to dispel concerns. We have seen how the share price has moved. My aim is to avoid that sort of impact - although, yes, I missed gains too,sure. I was mocked for suggesting investors keep an eye on allogeneic CART. It is a reality that IF it had succeeded in trials, autologous CART forecasts would drop massively. That is not scaremongering. As it turns out, allogeneic has struggled, which appears a good thing for OXB (particularly since NVS has or had its own allogeneic projects too). Allogeneic risk is reduced, but is still worth keeping an eye on. Blackstone recently invested $250M in it. They will have done more due diligence than any of us here. Point being, that what we need to see from OXB, is an array of robust long term income streams. At present, income is lumpy and hence the share price is volatile. What will the P&L look like when COVID subsides? I dont know? That may become clearer through 2022
catch007: Harry, I agree 2 deals announced is no coincidence, one is to take away pressure from the new NVS extension impact. I made no mention of the doc posts however there is some substance to my mind in some of his commentary. I politely beg to differ with you. NVS has been a bedrock blue chip customer of OXB. I suspect the contract extension has been rumbling on for several months as is the nature of such contracts whilst I understand the well argued point you make consider a couple of additional issues. Firstly prior to entering any contract renewal NVS would have issued OXB an RFP (request for proposal) document, this lays out the basis of the new deal to be negotiated. NVS will have ran its numbers and business case prior to issue. At this juncture OXB would note key points including exclusivity issues as such it would have time to discuss in parallel a deal with Arcellx who may have approached the company some time ago. Secondly if you review the commercial terms of NVS deal as the doc has stated I do not see a gain to OXB other than a contract renewal the appetite of NVS appears to have waned and £1m+ reduction in revenue is indeed substantial. Had NVS maintained its hunger to enhance the partnership again we would most likely have seen an upfront payment on the table to retain an element of exclusivity and volume deliverables as is the norm with commercial contracts agreed by OXB. Of course gutterhead and yourself may well be correct and I value your opinions I simply have an alternative view based on a long commercial business background. I must reiterate my faith in JD and OXB as an investor and continue to hold as I have done through the many peaks and troughs. This is a first class company imho.
harry s truman: I'm well known as a long term OXB fan and so can't help what will absolutely be some confirmation bias of my view / holding. However, OXB hasn't been anywhere near cashflow worries for years. It's a very long time since any of us here have mentioned a cash window, trying to work out the cash in bank against the burn and wondering where the next money comes from. These are very different times, starting from when Novartis partner with their CAR-T work it all began to look much more relaxing and by the time NN, Serum and others are taking these big equity stakes in new shares, well it's just a completely different place to be. Something like £60m in the bank at half year results plus another £50m from Serum shortly after that. Quite a nice place to be. Looking forward Boris seems committed to this world vaccination thing. It makes sense to give away those he overbought, but for any continuing commitment then I assume he will buy the cheapest. We're due a payment from Axovant / Sio when they begin their next cohort. Looking at their share price I'd imagine that they want to get that possibility of good news going as soon as possible. In the interims they mentioned a couple of times that they expected news on partnering before the year end. So 3 weeks now essentially, but we have been down this road before and if it's a deal in the second week of January then apart from the lost glory of winning the sweep, would it really hurt any of us? Downsides? Lots of things could give us a kick, but perhaps Evergrande is the one which worries the market most. Perhaps most likely is that it becomes a Chinese state company and one or two people disappear. Hard to tell at this point. I definitely wouldn't bet against a deal during the next 3 weeks for OXB.
Oxford Biomedica share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220119 02:21:14